** Shares of Akebia Therapeutics AKBA.O down 26.1% at $2.10 before the bell after co raises equity at steep discount
** Cambridge, Massachusetts-based co focused on kidney disease late Weds announced pricing of 25 mln shares at $2 for $50 mln gross proceeds
** Offering priced at 29.6% discount to last sale
** AKBA shares rose ~11% on Weds, capping a four-session winning streak in which they racked up a 68% gain
** On Mar 13, co reported Q4 results and said it expects its anemia drug, branded as Vafseo, to generate $10-$11 mln of net product revs in Q1
** Co to use net offering proceeds to fund working capital and general corporate purposes, including R&D and commercial activities for its products and pipeline candidates, per the SEC prospectus filing
** With ~236.2 mln shares outstanding, per the latest 10-K filing, AKBA has ~$670 mln market cap
** Leerink Partners and Piper Sandler are jt bookrunners for the stock offering
(Lance Tupper is a Reuters market analyst. The views expressed are his own)
((lance.tupper@tr.com 1-646-279-6380))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。